Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

Cyclophosphamide 3167Cisplatin 3163Carboplatin 2940Paclitaxel 2675Radiotherapy 2648Gemcitabine 2548pembrolizumab 2334Docetaxel 2158Bevacizumab 2129Fluorouracil 1822Capecitabine 1785Oxaliplatin 1713Dexamethasone 1591Nivolumab 1517Doxorubicin 1479Rituximab 1455Etoposide 1342Magnetic Resonance Spectroscopy 1270Irinotecan 1235Leucovorin 1217Cytarabine 1124Pemetrexed 1064Drug Therapy 1062fludarabine 1052Vincristine 958Specimen Handling 940Prednisone 927Cetuximab 921Lenalidomide 917Trastuzumab 903

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × small molecule inhibitor THX-B × Clear all
NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01657591 2023-01-19

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
21 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡